JP-1366: A novel and potent potassium-competitive acid blocker that is effective in the treatment of acid-related diseases.
Jin Mo KuJin Hee ChoKangjeon KimJi Yoon KimJong Yup KimJohn KimHyunju ChaBanyoon CheonPublished in: Pharmacology research & perspectives (2023)
The global prevalence of GERD is substantially increasing each year, and GERD is a chronic disease that reduces the quality of life of patients. The efficacy of conventional drugs is diverse, and most require long-term or lifetime administration; thus, the development of more effective therapeutic agents is needed. Herein, a more effective treatment for GERD was tested. We investigated whether JP-1366 affected gastric H+/K+-ATPase activity and used the Na+/K+-ATPase assay to confirm the selectivity of H+/K+-ATPase inhibition. To clarify the mechanism of enzyme inhibition, JP-1366 and TAK-438 were analyzed by Lineweaver-Burk. Also, we investigated the effects of JP-1366 in various models involving reflux esophagitis. We found that JP-1366 mediates strong, selective, and dose-dependent inhibition of H+/K+-ATPase. We found that JP-1366 significantly suppressed gastric acid secretion in histamine-treated pylorus-ligated rats in a dose-dependent manner. Additionally, we confirmed that JP-1366 inhibited histamine-stimulated gastric acid secretion in the HPD model. JP-1366 exhibited a more than 2-fold higher inhibitory effect on esophageal injury than TAK-438 in GERD lesions and had a more potent inhibitory effect in indomethacin- or aspirin-induced gastric ulcer rat models than TAK-438. Additionally, JP-1366 inhibited gastric ulcers. These results support the possibility that JP-1366 is a good candidate drug for treating acid-related diseases.
Keyphrases
- end stage renal disease
- type diabetes
- emergency department
- atrial fibrillation
- chronic kidney disease
- high glucose
- ejection fraction
- cardiovascular disease
- high throughput
- anti inflammatory
- high resolution
- prognostic factors
- replacement therapy
- smoking cessation
- single cell
- peritoneal dialysis
- acute coronary syndrome
- low dose
- angiotensin ii
- atomic force microscopy